Bank of Montreal Can Buys 74,414 Shares of Becton Dickinson and Co (BDX)

Bank of Montreal Can lifted its stake in Becton Dickinson and Co (NYSE:BDX) by 10.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 800,214 shares of the medical instruments supplier’s stock after purchasing an additional 74,414 shares during the period. Bank of Montreal Can owned about 0.30% of Becton Dickinson and worth $208,856,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in BDX. Fundsmith Equity Fund L.P. purchased a new stake in Becton Dickinson and during the 2nd quarter worth about $894,775,000. Hudson Bay Capital Management LP lifted its holdings in Becton Dickinson and by 119.9% during the 2nd quarter. Hudson Bay Capital Management LP now owns 166,094 shares of the medical instruments supplier’s stock worth $39,789,000 after buying an additional 90,564 shares during the last quarter. Parsons Capital Management Inc. RI lifted its holdings in Becton Dickinson and by 3.5% during the 2nd quarter. Parsons Capital Management Inc. RI now owns 7,262 shares of the medical instruments supplier’s stock worth $1,740,000 after buying an additional 246 shares during the last quarter. American Century Companies Inc. lifted its holdings in Becton Dickinson and by 0.7% during the 2nd quarter. American Century Companies Inc. now owns 1,196,281 shares of the medical instruments supplier’s stock worth $286,581,000 after buying an additional 7,843 shares during the last quarter. Finally, Kiwi Wealth Investments Limited Partnership purchased a new stake in Becton Dickinson and during the 2nd quarter worth about $9,161,000. Hedge funds and other institutional investors own 92.51% of the company’s stock.

Shares of BDX traded up $4.75 during midday trading on Friday, reaching $243.24. 94,251 shares of the stock were exchanged, compared to its average volume of 1,159,503. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and Co has a twelve month low of $196.77 and a twelve month high of $265.87. The stock has a market capitalization of $69.83 billion, a P/E ratio of 25.58, a price-to-earnings-growth ratio of 1.78 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, topping the Zacks’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The business had revenue of $4.28 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter in the previous year, the firm earned $2.46 earnings per share. The business’s revenue was up 41.0% compared to the same quarter last year. On average, equities research analysts forecast that Becton Dickinson and Co will post 11.01 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 28th. Stockholders of record on Friday, September 7th were given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date was Thursday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 31.65%.

A number of analysts have issued reports on BDX shares. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. Morgan Stanley lifted their price target on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a report on Thursday, October 4th. KeyCorp reaffirmed a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price target for the company in a report on Thursday, June 21st. Finally, Citigroup lifted their price target on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $253.79.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: Discount Rate

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply